Health Care • Biotechnology: Pharmaceutical Preparations
$1.31 ▼ -0.21
(-13.82%)
MKT CAP: $5.8M • VOL: 34.8K
52W L $1 52W H $13
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
SKYE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$58.2M | -$30.2M | -$34.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$55.9M | -$26.6M | -$37.6M |
| EBITDA (Normalized) | -$58.2M | -$28.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$43.1M | -$25.2M | -$14.0M |
| Capital Expenditures (CapEx) | $6.3K | $1.6M | — |
| Free Cash Flow (FCF) | -$43.1M | -$26.8M | -$14.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.9M | $68.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $20.0M | $68.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SKYE.